OKYO PHARMA LTD SP.ADR/65 (F:OK10) — Market Cap & Net Worth
Market Cap & Net Worth: OKYO PHARMA LTD SP.ADR/65 (OK10)
OKYO PHARMA LTD SP.ADR/65 (F:OK10) has a market capitalization of $38.38 Million (€32.83 Million) as of May 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #22828 globally and #2008 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OKYO PHARMA LTD SP.ADR/65's stock price €1.36 by its total outstanding shares 28219900 (28.22 Million).
OKYO PHARMA LTD SP.ADR/65 Market Cap History: 2022 to 2026
OKYO PHARMA LTD SP.ADR/65's market capitalization history from 2022 to 2026. Data shows change from $65.65 Million to $44.87 Million (-9.08% CAGR).
OKYO PHARMA LTD SP.ADR/65 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OKYO PHARMA LTD SP.ADR/65's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OK10 by Market Capitalization
Companies near OKYO PHARMA LTD SP.ADR/65 in the global market cap rankings as of May 3, 2026.
Key companies related to OKYO PHARMA LTD SP.ADR/65 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
OKYO PHARMA LTD SP.ADR/65 Historical Marketcap From 2022 to 2026
Between 2022 and today, OKYO PHARMA LTD SP.ADR/65's market cap moved from $65.65 Million to $ 44.87 Million, with a yearly change of -9.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €44.87 Million | 0.00% |
| 2025 | €44.87 Million | 0.00% |
| 2024 | €44.87 Million | 0.00% |
| 2023 | €44.87 Million | -31.66% |
| 2022 | €65.65 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of OKYO PHARMA LTD SP.ADR/65 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.38 Million USD |
| MoneyControl | $38.38 Million USD |
| MarketWatch | $38.38 Million USD |
| marketcap.company | $38.38 Million USD |
| Reuters | $38.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OKYO PHARMA LTD SP.ADR/65
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptid… Read more